Trial Profile
Study of Immunogenicity of Anti-HAV Immunisation in HIV-1 Infected Patients, Co-infected or Not With HBV and/or HCV. HEP.A.VAC Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Hepatitis A vaccine inactivated (Primary)
- Indications Hepatitis A
- Focus Pharmacodynamics
- Acronyms HEPAVAC
- 28 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jun 2011 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 01 Nov 2008 Results published in the Journal of Acquired Immune Deficiency Syndromes, according to 1133004.